7 minute read
Apr. 30, 2023

A Treg-Modulating IKZF2 (Helios) Glue Degrader for Cancer Immunotherapy

DKY709

oral IKZF2-selective molecular glue degrader Ph. I/Ib for adv. solid tumors opt. of pomalidomide analog Cell Chemical Biology, March 1, 2023 Novartis, Cambridge, MA

drughunter.com
Drug Hunter Team

Tumors can evade the immune system through the recruitment of regulatory T cells (Treg) which limit the activation and expansion of effector T cells (Teff). IKZF2 (Helios) is an Ikaros transcription factor family member that is expressed in a majority of Treg cells [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in